DE10299033I1 - Formoterol und Budesonide enthaltende Zusammensetzung - Google Patents

Formoterol und Budesonide enthaltende Zusammensetzung

Info

Publication number
DE10299033I1
DE10299033I1 DE2002199033 DE10299033C DE10299033I1 DE 10299033 I1 DE10299033 I1 DE 10299033I1 DE 2002199033 DE2002199033 DE 2002199033 DE 10299033 C DE10299033 C DE 10299033C DE 10299033 I1 DE10299033 I1 DE 10299033I1
Authority
DE
Germany
Prior art keywords
budesonide
separately
formoterol
composition containing
esp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE2002199033
Other languages
English (en)
Other versions
DE10299033I2 (de
Inventor
Christer Carl Gustav Carling
Jan William Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8208509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10299033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE10299033I1 publication Critical patent/DE10299033I1/de
Application granted granted Critical
Publication of DE10299033I2 publication Critical patent/DE10299033I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
DE2002199033 1991-12-18 1992-12-07 Formoterol und Budesonide enthaltende Zusammensetzung. Active DE10299033I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91311761 1991-12-18
PCT/EP1992/002826 WO1993011773A1 (en) 1991-12-18 1992-12-07 New combination of formoterol and budesonide

Publications (2)

Publication Number Publication Date
DE10299033I1 true DE10299033I1 (de) 2003-01-23
DE10299033I2 DE10299033I2 (de) 2005-07-07

Family

ID=8208509

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69232462T Expired - Lifetime DE69232462T2 (de) 1991-12-18 1992-12-07 Formoterol und budesonide enthaltende zusammensetzung
DE2002199033 Active DE10299033I2 (de) 1991-12-18 1992-12-07 Formoterol und Budesonide enthaltende Zusammensetzung.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69232462T Expired - Lifetime DE69232462T2 (de) 1991-12-18 1992-12-07 Formoterol und budesonide enthaltende zusammensetzung

Country Status (21)

Country Link
US (2) US5674860A (de)
JP (1) JP3342484B2 (de)
AT (1) ATE213946T1 (de)
AU (1) AU673660C (de)
CA (2) CA2123909C (de)
CZ (2) CZ288032B6 (de)
DE (2) DE69232462T2 (de)
DK (1) DK0613371T3 (de)
ES (1) ES2172510T3 (de)
HK (1) HK1010339A1 (de)
HR (1) HRP921445B1 (de)
HU (2) HU227519B1 (de)
IS (1) IS3959A (de)
NO (2) NO306452B1 (de)
NZ (1) NZ246050A (de)
PT (1) PT613371E (de)
SG (1) SG48301A1 (de)
SI (1) SI9200403B (de)
SK (2) SK285910B6 (de)
WO (1) WO1993011773A1 (de)
YU (1) YU49083B (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DK1393721T3 (da) * 1997-03-20 2009-03-30 Schering Corp Doseringsform af pulveragglomerater
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
ID24063A (id) * 1997-06-27 2000-07-06 Astra Ab Kombinasi obat anti asma
AU766637B2 (en) * 1997-09-19 2003-10-23 Astrazeneca Ab New use for budesonide and formoterol
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
CN1149078C (zh) * 1998-02-09 2004-05-12 乔尔·博朗尼克 治疗慢性胃肠道炎症的制剂
CN1289091C (zh) * 1998-02-11 2006-12-13 Rtp药品公司 治疗炎症的药物组合物和相关用途
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6234167B1 (en) 1998-10-14 2001-05-22 Chrysalis Technologies, Incorporated Aerosol generator and methods of making and using an aerosol generator
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
EP2266548B1 (de) 1998-11-13 2020-05-20 Jagotec AG Trockenpulver zur inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
JP5116928B2 (ja) * 1999-09-13 2013-01-09 ブリッジ ファーマ、インコーポレイテッド ケトチフェン及びその治療上有効な代謝産物の光学活性異性体
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
CO5251465A1 (es) * 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US6491233B2 (en) 2000-12-22 2002-12-10 Chrysalis Technologies Incorporated Vapor driven aerosol generator and method of use thereof
US6681998B2 (en) 2000-12-22 2004-01-27 Chrysalis Technologies Incorporated Aerosol generator having inductive heater and method of use thereof
US6701921B2 (en) 2000-12-22 2004-03-09 Chrysalis Technologies Incorporated Aerosol generator having heater in multilayered composite and method of use thereof
US6501052B2 (en) 2000-12-22 2002-12-31 Chrysalis Technologies Incorporated Aerosol generator having multiple heating zones and methods of use thereof
US6799572B2 (en) 2000-12-22 2004-10-05 Chrysalis Technologies Incorporated Disposable aerosol generator system and methods for administering the aerosol
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US6568390B2 (en) 2001-09-21 2003-05-27 Chrysalis Technologies Incorporated Dual capillary fluid vaporizing device
US6640050B2 (en) 2001-09-21 2003-10-28 Chrysalis Technologies Incorporated Fluid vaporizing device having controlled temperature profile heater/capillary tube
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
DE60227691D1 (de) 2001-11-01 2008-08-28 Nektar Therapeutics Sprühtrocknungsverfahren
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US6681769B2 (en) 2001-12-06 2004-01-27 Crysalis Technologies Incorporated Aerosol generator having a multiple path heater arrangement and method of use thereof
US6804458B2 (en) 2001-12-06 2004-10-12 Chrysalis Technologies Incorporated Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6701922B2 (en) 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
SE0203376D0 (sv) * 2002-11-15 2002-11-15 Astrazeneca Ab New process
EP1572217B1 (de) 2002-12-12 2008-08-20 Nycomed GmbH Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
US7311790B2 (en) * 2003-04-25 2007-12-25 Siemens Power Generation, Inc. Hybrid structure using ceramic tiles and method of manufacture
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AU2003254429A1 (en) 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
CA2572790C (en) 2004-07-16 2014-12-23 Laboratorios Almirall, S.A. Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
WO2007011743A2 (en) 2005-07-14 2007-01-25 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US20070293460A1 (en) * 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
CA2673553C (en) 2006-12-22 2014-06-17 Laboratorios Almirall, S.A. Breath actuated metering slide for a powder inhaler
EP1944018A1 (de) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Mikronisierte Partikel mit niedrigdosierten Wirkstoffen für Pulverzubereitungen zur Inhalation
EP2327403A3 (de) 2007-02-19 2011-08-31 Cipla Limited Pharmazeutische kombinationen aus mindestens zwei bronchodilatatoren
EP1982709A1 (de) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Verwendung einer Zusammensetzung mit Formoterol und Beclomethason-Dipropionat zur Vorbeugung oder Behandlung von akutem Asthma
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20110132357A1 (en) 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
JP2013517294A (ja) * 2010-01-15 2013-05-16 リセラ，インク． 凍結乾燥ケーキ製剤
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2012154725A2 (en) * 2011-05-09 2012-11-15 University Of Houston Steroid-sparing effects of beta-adrenergic inverse agonists and use thereof
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
EP2968152B2 (de) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Verfahren und systeme zum konditionieren von teilchenförmigen kristallinen materialien
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
ES2796177T3 (es) * 2015-12-04 2020-11-26 Mexichem Fluor Sa De Cv Composición farmacéutica

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (de) * 1972-05-19 1975-08-18 Bofors Ab
AU644094B2 (en) * 1989-09-08 1993-12-02 Glaxo Group Limited Medicaments
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate

Also Published As

Publication number Publication date
CZ143494A3 (en) 1994-12-15
CA2123909A1 (en) 1993-06-24
HU227519B1 (en) 2011-07-28
US5674860A (en) 1997-10-07
ES2172510T3 (es) 2002-10-01
HK1010339A1 (en) 1999-06-17
NO2001014I2 (no) 2007-06-11
HUT75156A (en) 1997-04-28
YU106192A (sh) 1996-01-08
CZ288032B6 (cs) 2001-04-11
NZ246050A (en) 1995-12-21
AU673660B2 (en) 1996-11-21
DE69232462D1 (de) 2002-04-11
DK0613371T3 (da) 2002-05-13
AU3085892A (en) 1993-07-19
SK73394A3 (en) 1995-03-08
HRP921445A2 (en) 1994-12-31
ATE213946T1 (de) 2002-03-15
YU49083B (sh) 2003-10-31
SI9200403B (en) 2001-12-31
NO942116L (de) 1994-06-07
CA2123909C (en) 2002-10-01
SG48301A1 (en) 1998-04-17
SI9200403A (en) 1993-06-30
JP3342484B2 (ja) 2002-11-11
JPH07502036A (ja) 1995-03-02
CZ291455B6 (cs) 2003-03-12
NO306452B1 (no) 1999-11-08
HU0004452D0 (de) 2001-01-29
WO1993011773A1 (en) 1993-06-24
SK285910B6 (sk) 2007-10-04
CA2356145A1 (en) 1993-06-24
DE10299033I2 (de) 2005-07-07
DE69232462T2 (de) 2002-10-10
NO942116D0 (no) 1994-06-07
SK282826B6 (sk) 2002-12-03
HU9401843D0 (en) 1994-09-28
IS3959A (is) 1993-06-19
AU673660C (en) 2002-07-25
HRP921445B1 (en) 2011-08-31
US5972919A (en) 1999-10-26
PT613371E (pt) 2002-07-31

Similar Documents

Publication Publication Date Title
ATE213946T1 (de) Formoterol und budesonide enthaltende zusammensetzung
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
DE69005951D1 (de) Medikamente enthaltend Salmeterol und Fluticason.
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
ATE77947T1 (de) Pentamidin enthaltende pharmazeutische zusammensetzungen.
DE69002718D1 (de) Medikamente.
KR910005858A (ko) 지방산 요법
DK0533896T3 (de)
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
AR002946A1 (es) Un conjunto para uso en el tratamiento o la prevencion de la osteoporosis en los mamiferos de acuerdo con una dieta ciclica.
KR910005856A (ko) 호흡기 질환 치료용 제약 조성물